Atrium Therapeutics Inc.
RNA | NASDAQ
$8.41
+$0.14 (+1.69%)
Nov 2, 2026, 9:53 AM ET · Market open
Fiscal Quarter Period Ending | Q2 2026 Jun 30, 2026 | Q1 2026 Mar 31, 2026 | Q4 2025 Dec 31, 2025 | Q3 2025 Sep 30, 2025 |
|---|---|---|---|---|
Cash & Equivalents | 72.65M | 267.85M | 270M | 270M |
Short-Term Investments | 191.57M | n/a | n/a | n/a |
Long-Term Investments | 106K | 415K | n/a | n/a |
Other Long-Term Assets | n/a | n/a | n/a | n/a |
Receivables | n/a | 15M | n/a | n/a |
Inventory | n/a | n/a | n/a | n/a |
Other Current Assets | 6.33M | 138K | 1.31M | n/a |
Total Current Assets | 275.05M | 285.57M | 272.85M | 271.26M |
Property-Plant & Equipment | 5.36M | 6.38M | 5.51M | 6.28M |
Goodwill & Intangibles | n/a | n/a | n/a | n/a |
Total Long-Term Assets | 5.46M | 6.8M | 5.51M | 6.28M |
Total Assets | 280.51M | 292.36M | 278.35M | 277.54M |
Account Payables | 3.51M | 807K | 4.4M | 451K |
Deferred Revenue | 9.04M | 9.34M | 21.64M | 19.12M |
Short-Term Debt | 1.68M | 2.68M | n/a | n/a |
Other Current Liabilities | 13.31M | 6.98M | 3.15M | 2.59M |
Total Current Liabilities | 31.51M | 21.91M | 41.8M | 31.74M |
Long-Term Debt | n/a | n/a | n/a | n/a |
Other Long-Term Liabilities | 775K | n/a | 574K | 574K |
Total Long-Term Liabilities | 34.43M | 36.35M | 29.27M | 32.95M |
Total Liabilities | 65.94M | 58.26M | 71.07M | 64.69M |
Total Debt | 1.68M | 2.68M | 3.67M | 4.28M |
Book Value | 214.58M | 234.1M | 207.29M | 212.85M |
Book Value Per Share | 12.54 | 13.69 | 12.11 | n/a |
Common Stock | 16K | 16K | 17K | 17K |
Retained Earnings | -8.06M | 12.13M | n/a | n/a |
Comprehensive Income | -235K | n/a | n/a | n/a |
Shareholders Equity | 214.58M | 234.1M | 207.29M | 212.85M |
Total Investments | 191.67M | 415K | n/a | n/a |
Add to Watchlist
Select watchlists to add or remove RNA